Table 3.
Patterns | Number of isolates (n = 156) | Number (%) |
---|---|---|
Monoresistant | 43 | 27.56 |
OFX | 34 | 21.79 |
KAN | 1 | 0.64 |
PTO | 2 | 1.28 |
PAS | 6 | 3.85 |
Multiresistant | 38 | 24.36 |
OFX + KAN | 3 | 1.92 |
OFX + KAN + AMK | 2 | 1.28 |
OFX + KAN + CAP | 1 | 0.64 |
OFX + KAN + PAS | 1 | 0.64 |
OFX + KAN + CAP + AMK | 4 | 2.56 |
OFX + KAN + PTO + AMK | 1 | 0.64 |
OFX + KAN + PTO + PAS + AMK | 1 | 0.64 |
OFX + KAN + CAP + PAS + AMK | 5 | 3.21 |
OFX + KAN + CAP + PTO + PAS + AMK | 1 | 0.64 |
OFX + AMK | 1 | 0.64 |
OFX + PTO | 5 | 3.21 |
OFX + PAS | 7 | 4.49 |
KAN + AMK | 2 | 1.28 |
KAN + CAP + AMK | 2 | 1.28 |
KAN + PTO + AMK | 1 | 0.64 |
KAN + PAS | 1 | 0.64 |
Susceptible | 75 | 48.08 |
aThe second-line drugs are as follows: OFX, KAN, AMK, CAP, PTO, or PAS; bMDR is defined as Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampin.